Autobio Diagnostics Co., Ltd. (SHA:603658)

China flag China · Delayed Price · Currency is CNY
34.35
+0.90 (2.69%)
Apr 1, 2026, 3:00 PM CST
Market Cap19.63B -17.3%
Revenue (ttm)4.22B -7.9%
Net Income1.10B -13.7%
EPS1.92 -12.8%
Shares Out571.42M
PE Ratio17.90
Forward PE17.25
Dividend1.26 (3.77%)
Ex-Dividend DateMay 26, 2025
Volume3,449,698
Average Volume1,806,900
Open33.84
Previous Close33.45
Day's Range33.33 - 34.39
52-Week Range32.55 - 43.14
Beta0.00
RSI43.38
Earnings DateApr 23, 2026

About Autobio Diagnostics

Autobio Diagnostics Co., Ltd. engages in the research and development, production, marketing, sale, and service of clinical diagnostic products in China and internationally. The company offers immunoassay, biochemistry, and microbiology products; reagents and instruments; and technical and support, and training services, as well as engages in biology research and development activities. Its immunoassay products consist of AutoLumo S900 and AutoLumo A1860 that provides user experience for small and medium size labs; AutoLumo A6200/A6600, an auto... [Read more]

Sector Healthcare
Founded 1998
Employees 5,773
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 603658
Full Company Profile

Financial Performance

In 2024, Autobio Diagnostics's revenue was 4.47 billion, an increase of 0.62% compared to the previous year's 4.44 billion. Earnings were 1.19 billion, a decrease of -1.89%.

Financial Statements